Stabilized Production of Ribozymes, iRNA, mRNA and Other Gene Products

Tech ID
FN97001
Background

Wistar researchers have developed a novel method to stabilize introns that offers the potential for stable production of ribozymes, iRNA, mRNA and related gene products. Using the Wistar technology, stabilized intron compositions are prepared with a sequence from the LAT intron of the HSV-1 virus. Polynucleotide encoding sequences are then ligated into a stabilized intron, resulting in a 105 -fold increase in stability. Unlike typical introns that rapidly degrade within seconds after excision, these stabilized introns have a half life of 24 hours (Thomas et al. 2002. J. Virol., 76, 532-540). The increased stability has been demonstrated in several models, indicating that the method is neither cell type- nor species-specific and can be applied to both eukaryotic and yeast expression systems.

These methods and compositions are useful for:

- Stabilizing a gene transcript to permit enhanced expression, and increased production, of a recombinant gene product.

- Production of vectors and gene products for research reagents, markers of gene production, and diagnostic and therapeutic compositions.

- Markers for determining whether a gene of interest is being transcribed, particularly for identification of genes transcribed only in a selected stage of the cell cycle.

Key Words
antisense), expression system, gene therapy, reagent or vector), Research tool (DNA/RNA synthesis, ribozyme, RNA, screening, therapeutic (gene expression
Applications and Advantages

Stabilized intron compositions can be used to enable and enhance the production of ribozymes, iRNA, mRNA, and gene products with unstable mRNA for research, diagnosis, gene therapy and recombinant protein production.

Intellectual Property Status

U.S. Patent No. 6,159,710.

Licensing Opportunity

Licenses are available for research, diagnostic and therapeutic use.